PL3149172T3 - Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach - Google Patents

Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach

Info

Publication number
PL3149172T3
PL3149172T3 PL15729289T PL15729289T PL3149172T3 PL 3149172 T3 PL3149172 T3 PL 3149172T3 PL 15729289 T PL15729289 T PL 15729289T PL 15729289 T PL15729289 T PL 15729289T PL 3149172 T3 PL3149172 T3 PL 3149172T3
Authority
PL
Poland
Prior art keywords
organs
compositions
methods
reperfusion injury
ischemia reperfusion
Prior art date
Application number
PL15729289T
Other languages
English (en)
Inventor
Elizabeth C. Squiers
Shai Erlich
Daniel ROTHENSTEIN
Nir Sharon
Daniel J. ODENHEIMER
Elena Feinstein
Original Assignee
Quark Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals, Inc. filed Critical Quark Pharmaceuticals, Inc.
Publication of PL3149172T3 publication Critical patent/PL3149172T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15729289T 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach PL3149172T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004239P 2014-05-29 2014-05-29
PCT/US2015/032499 WO2015183842A1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs
EP15729289.7A EP3149172B1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs

Publications (1)

Publication Number Publication Date
PL3149172T3 true PL3149172T3 (pl) 2018-10-31

Family

ID=53398201

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15729289T PL3149172T3 (pl) 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach
PL18183735T PL3444349T3 (pl) 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18183735T PL3444349T3 (pl) 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach

Country Status (18)

Country Link
US (3) US20170081665A1 (pl)
EP (2) EP3149172B1 (pl)
JP (2) JP2017521374A (pl)
KR (1) KR20170007492A (pl)
CN (2) CN106661579B (pl)
AU (1) AU2015267160B2 (pl)
BR (1) BR112016028009A2 (pl)
CA (1) CA2949109A1 (pl)
DK (2) DK3149172T3 (pl)
ES (2) ES2862185T3 (pl)
HU (2) HUE054226T2 (pl)
IL (2) IL248912A0 (pl)
LT (2) LT3149172T (pl)
MX (2) MX373950B (pl)
PL (2) PL3149172T3 (pl)
PT (2) PT3444349T (pl)
SI (2) SI3149172T1 (pl)
WO (1) WO2015183842A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
US12091664B2 (en) 2018-01-12 2024-09-17 University Of Massachusetts Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation
GB202016863D0 (en) * 2020-10-23 2020-12-09 Causeway Therapeutics Ltd Microrna-29 compounds, compositions and uses in therapy
CN118354797A (zh) * 2021-12-22 2024-07-16 株式会社Na疫苗研究所 用于预防或治疗缺血-再灌注损伤的组合物以及其用途
KR20240154159A (ko) * 2023-04-17 2024-10-25 재단법인 아산사회복지재단 miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
CN118460648B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团（天津）股份有限公司 一种qpi-1002的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
AU1435492A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
NZ513487A (en) 1999-01-29 2003-02-28 Univ Illinois The use of a P53 inhibitor for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US20060105975A1 (en) 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
PL1799269T3 (pl) * 2004-09-28 2017-01-31 Quark Pharmaceuticals, Inc. Oligorybonukleotydy i sposoby ich zastosowania do leczenia łysienia, ostrej niewydolności nerek i innych chorób
EP1989307B1 (en) 2006-02-08 2012-08-08 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
US8614309B2 (en) * 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
WO2009155504A2 (en) * 2008-06-20 2009-12-23 The Children's Medical Center Corporation Methods for the modulation of angiogenesis
JP2012529430A (ja) 2009-06-08 2012-11-22 クォーク ファーマシューティカルズ インコーポレーティッド 慢性腎臓疾患の治療方法
NZ599237A (en) 2009-11-26 2014-03-28 Quark Pharmaceuticals Inc Sirna compounds comprising terminal substitutions
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2011138966A1 (ja) 2010-05-06 2011-11-10 ダイヤニトリックス株式会社 微生物触媒を用いたアクリルアミドの製造方法
WO2012068381A2 (en) * 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
EP2649181B1 (en) 2010-12-06 2016-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US9176487B2 (en) * 2011-10-24 2015-11-03 Mayo Foundation For Medical Education And Research Methods and materials for reducing the risk of infections
EP2895608B1 (en) * 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof

Also Published As

Publication number Publication date
PL3444349T3 (pl) 2021-06-28
US20170081665A1 (en) 2017-03-23
CA2949109A1 (en) 2015-12-03
LT3149172T (lt) 2018-09-10
AU2015267160B2 (en) 2021-07-29
PT3444349T (pt) 2021-04-06
SI3444349T1 (sl) 2021-07-30
KR20170007492A (ko) 2017-01-18
HUE040092T2 (hu) 2019-02-28
IL278144B (en) 2021-07-29
JP2020128383A (ja) 2020-08-27
MX373950B (es) 2020-07-13
BR112016028009A2 (pt) 2018-02-20
HUE054226T2 (hu) 2021-08-30
MX2020005794A (es) 2020-10-28
JP2017521374A (ja) 2017-08-03
SI3149172T1 (sl) 2018-10-30
EP3149172A1 (en) 2017-04-05
IL248912A0 (en) 2017-01-31
US20170335327A1 (en) 2017-11-23
CN106661579B (zh) 2020-12-04
EP3444349A1 (en) 2019-02-20
EP3149172B1 (en) 2018-07-18
DK3149172T3 (en) 2018-08-20
US9868953B2 (en) 2018-01-16
CN106661579A (zh) 2017-05-10
MX2016015635A (es) 2017-04-25
US20180305696A1 (en) 2018-10-25
LT3444349T (lt) 2021-04-12
AU2015267160A1 (en) 2016-12-01
DK3444349T3 (da) 2021-04-12
IL278144A (en) 2020-11-30
EP3444349B1 (en) 2021-01-06
ES2862185T3 (es) 2021-10-07
PT3149172T (pt) 2018-10-08
AU2015267160A8 (en) 2016-12-08
CN112410336A (zh) 2021-02-26
ES2683869T3 (es) 2018-09-28
WO2015183842A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
GB2535253B (en) Compositions and methods
GB2534873B (en) Improvements in and relating to horseshoes
IL278144B (en) Compositions for the prevention of organ damage resulting from ischemia-reperfusion
IL246879A0 (en) Preparations of Epilimod and methods of using them
GB201522204D0 (en) Improvements in or relating to clamping devices
PL3220908T3 (pl) Kompozycje i sposoby leczenia endometriozy
ZA201605109B (en) Compositions and methods for treating neutropenia
IL264760B1 (en) Regional ischemia/reperfusion injury
GB201518802D0 (en) Improvements in and relating to nozzles
EP3104896A4 (en) Compositions and methods for treating liver injury
GB201401373D0 (en) Compositions for cells lysis and uses thereof
IL246637A0 (en) Preparations and methods for the treatment of intracerebral hemorrhage
PT3160263T (pt) Composições para prevenção de infeções
GB201402915D0 (en) Compositions and methods
GB2530075B (en) Improvements in and relating to eyewashing
PT3210628T (pt) Métodos para complexos de frutoborato
PL2990058T3 (pl) Ulepszone kompozycje i sposoby dla kompleksów fruktoboranowych
GB201704057D0 (en) Improvements in agricultural equipment
GB201509274D0 (en) Improvements in agricultural equipment
GB201417432D0 (en) Improvements in and relating to pipe-breaking
GB201403212D0 (en) Compositions and methods
GB201419559D0 (en) Therapeutic compositions and methods
HUE038776T2 (hu) Szinergikus felületaktív anyag összetétel
GB201412345D0 (en) Improvements in and relating to devices
GB201404831D0 (en) Animalistic studies in nature